This post was originally published on this site 68Ga-PSMA-11 PET scans are highly accurate, reproducible, and safe for detecting prostate cancer that has come back after prior therapy with prostate surgery or radiation therapy, a study shows. The report, “Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer,” was published in the journal JAMA Oncology.…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Lynparza Plus Investigational Alpelisib Is Promising for Epithelial Ovarian Cancer
This post was originally published on this site A combination of Lynparza (olaparib) and the investigational PI3K inhibitor alpelisib is safe for the treatment of recurrent epithelial ovarian cancer and induces at least stable disease in more than 80% of patients, results from a Phase 1 trial show. Importantly, the combination was effective in women…
SCMR Promotes Heart MRIs During National Sarcoidosis Awareness Month
This post was originally published on this site During April, National Sarcoidosis Awareness Month, the Society for Cardiovascular Magnetic Resonance (SCMR) is promoting the use of cardiac imaging to non-invasively assess changes in patients’ heart tissue and overall cardiac function. Sarcoidosis is marked by an overreactive immune system and the resulting formation of small clumps of…
Getting Back Up Again
This post was originally published on this site It’s been a tumultuous year so far (to say the least). I write this while lying sprawled out on a deck chair in the garden, watching as the African sun slips beneath the horizon of the Atlantic Ocean. I’m on a two-week holiday to my native city…
Antibiotic in Long Use for Leprosy, Clofazimine, May Treat Triple-negative Breast Cancer, Mouse Study Suggests
This post was originally published on this site Clofazimine, an antibiotic long used for treating leprosy and tuberculosis, may be repurposed as a promising potential treatment for triple-negative breast cancer, a study in mice suggests. The treatment targets the Wnt signaling pathway – key in triple-negative breast and other cancer types – preventing cells from growing,…
Neurological Disease Expert Joins MDA’s Research Team
This post was originally published on this site The Muscular Dystrophy Association (MDA) has recently added to its research team an expert in neurological diseases in order to enhance and improve its healthcare service programs. MDA has hired Lianna R. Orlando, Scientific Program Officer who comes to MDA from Fidelity Biosciences Research Initiative. There at Fidelity, she…
University of Helsinki Researchers Discover Vitamin B3 Form that is Effective in Attenuating Mitochondrial Myopathy Progression
This post was originally published on this site Researchers from the University of Helsinki recently found that a vitamin B3 form might be effective in attenuating the progression of mitochondrial myopathy. The study is published in the journal EMBO Molecular Medicine. Mitochondrial disorders are caused by respiratory chain deficiency (RCD) and are the most usual…
Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment
This post was originally published on this site Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple myeloma patients — at several sites in the U.S. The trial, called MUNDI-01, will assess multiple doses of the therapy to determine its safety, cell expansion and persistence,…
Velcade Add-on Doesn’t Improve Survival Outcomes in Newly Diagnosed DLBCL, Trial Shows
This post was originally published on this site Adding Velcade (bortezomib) to standard chemotherapy is well-tolerated but does not improve the survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL), even after stratifying patients according to their cell of origin, a Phase 3 trial shows. The study, “Gene-expression profiling of bortezomib added to standard…
Liquid Biopsy Test Helping Select People with Advanced Prostate Cancer for Phase 2 Study of Pamiparib
This post was originally published on this site A Phase 2 trial testing the investigational PARP inhibitor pamiparib in treating metastatic castration-resistant prostate cancer patients is using Epic Sciences‘ novel liquid biopsy assay to select those patients who are most likely to benefit from treatment, the company announced. Epic’s test is designed to collect circulating tumor…
BioAtla and BeiGene Enter Collaboration to Develop BioAtla’s BA3071 Cancer Therapy
This post was originally published on this site BioAtla and BeiGene entered into a collaboration agreement for the development, production, and commercialization of BioAtla’s BA3071, an investigational anti-CTLA-4 checkpoint blockade antibody. Checkpoint blockade therapies are based on the principle of removing the “brakes” of the immune system, in order to use the power of the…
AstraZeneca Teams with Daiichi Sankyo to Speed Development of HER2-positive Advanced Breast Cancer Therapy
This post was originally published on this site AstraZeneca is starting a collaboration with Daiichi Sankyo for the global production and commercialization of trastuzumab deruxtecan (DS-8201), a novel antibody-drug conjugate under clinical studies for the treatment of advanced HER2-positive breast cancer, and other types of solid tumors. The investigational therapy was granted fast track status by the…